🚽 Is Gem/Doce the Future for Bladder Cancer Treatment? Gem/Doce shows promise as a first-line treatment for BCG-naïve high-risk NMIBC, offering new hope during BCG shortages. 📈 Efficacy - 3-year high-grade recurrence-free survival is 80% 🔬 Tolerability - Only 8% stopped due to adverse reactions 📊 Future Potential - Phase 3 trials needed for standard care status #BladderCancer #GemDoce #ClinicalTrials tnyp.me/xRumFw21/x

Priority review by the @FDA for neoadjuvant EV+Durvalumab based on #VOLGA study which is not yet presented!, but soon at #ESMO26 Interesting—and somewhat unusual—to see a Priority Review announcement with a PDUFA action date already in Q4 2026. The perioperative bladder cancer space is moving very fast. #bladdercancer #GUonc @OncoAlert @DanaFarber_GU @myESMO @AstraZeneca @AstraZenecaUS @OncoBellmunt @tompowles1 astrazeneca-us.com/content/a…

🚨 FDA Priority Review granted for durvalumab plus neoadjuvant enfortumab vedotin in muscle-invasive #BladderCancer : VOLGA Update Source: AstraZeneca The submission is supported by Phase III VOLGA results showing statistically significant and clinically meaningful improvements in event-free survival and overall survival. @DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @AlbigesL, @cdanicas, @amerseburger, @sonpavde, @DrDanielHeng, @declangmurphy, @seanmmcbride, @HHammersMD, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @scocmem, @ravikanesvaran, @AmandaNizamMD, @drenriquegrande, @BraunMDPhD, @EfstathiouEleni, @nataliagandur, @crisbergerot, @realbowtiedoc, @FernandoOnco, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @BRicciutiMD, @HHorinouchi, @UOzkerim, @p_ciracimd, @DrMirallas

FDA grants Priority Review for the VOLGA trail, in which 3 neoadjuvant cycles of EV and a year of Perioperative durvalumab was given for patients with muscle invasive bladder cancer. Press release states an EFS and OS advantage. Data will be presented #ESMO26 @OncoAlert @myESMO @Annals_Oncology astrazeneca-us.com/content/a…

Cribriform pattern and intraductal carcinoma predicted biochemical recurrence after radical prostatectomy (adjusted HR 2.59) in this meta-analysis. Standardized reporting may strengthen postoperative risk stratification. 🔗[doi.org/10.1038/s41391-026-0…] #ProstateCancer #Pathology

JUST IN: @FDA approves the combo of Lenvatinib+HIF2 inhibitor Belzutifan in advanced clear cell renal cell carcinoma following PD1/L1 inhibitor. Results based on Litespark-011 trial led by @motzermd @DrDanielHeng @SchmidigerManu1 @ASCO @myESMO @AACR @kidneycan @DanaFarber_GU @OncoAlert

Check out this commentary by @VivekSubbiah 👇🏼 Terms like “triple-negative”, “wild-type” or “non-small cell” feel more outdated as we move beyond the microscope and our understanding of cancer biology and therapeutics evolves. @Annals_Oncology @OncoAlert annalsofoncology.org/article…

David J. Hunter, MB, BS, FMedSci, and Michael Inouye, PhD, review the ways common genetic variants, polygenic risk scores, and pharmacogenomic genotyping may be useful in the prevention of common diseases and the treatment of common diseases after diagnosis. Read the Review Article “Clinical Uses of Common Genetic Variants Associated with Common Diseases”: nej.md/4Amwv0F

Upfront apalutamide changes how men progress in mCSPC, not only when. 📉 24-month PSA-first CRPC 19% vs 52% on placebo 📊 Radiographic-first CRPC essentially unchanged, 13% vs 14% 🔍 Baseline visceral metastasis was associated with the radiographic route in both arms Post hoc of TITAN, hypothesis generating Acknowledging more frequent imaging progression than previously understood i'm scanning every 6 months and often alternatng high res CT with PSMA PET. How closely are you imaging visceral-metastatic patients on an ARPI? 👉 doi.org/10.1016/j.euf.2026.0… #ProstateCancer #mCSPC #GUonc

SHR-A2102, a nectin-4 directed antibody–drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial - The Lancet Oncology thelancet.com/journals/lanon… @OncoAlert @tompowles1 @GuardConsortium

Biochemical recurrence after radical prostatectomy raises 3 practical questions: when PSMA-PET adds value, how far salvage radiotherapy should extend and who benefits from ADT. Early treatment and individualized risk remain central. 🔗[doi.org/10.1038/s41391-026-0…] #ProstateCancer

👏 La enfermera #H12O Paloma Ruiz colidera estudio internacional para aumentar seguridad en el manejo de catéteres. ✅ Unificar criterios para mejorar cuidados y reducir riesgos. 🔝 Importancia de la enfermería en la investigación dentro del 12. ▶️ c.madrid/73llf

Worth reading this editorial by @BethN01 in @Annals_Oncology. As ICIs move earlier, duration, treatment & patient-informed toxicity matter. Wearables and ePROs may give us a more complete picture. @OncoAlert annalsofoncology.org/article…

🎥 Así vivimos el #GUARDSymposium2026. Tres jornadas de conocimiento compartido, debate y colaboración para seguir avanzando en la investigación y el abordaje de los tumores genitourinarios. Gracias a todos los ponentes, asistentes, colaboradores y entidades que lo habéis hecho posible. Nos vemos en 2027. #GUARDConsortium #GUOncology #InvestigaciónClínica #TumoresGenitourinarios @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist

Now online: Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts doi.org/10.1158/2159-8290.CD…

PROTEUS moves radical prostatectomy into a multimodal era: perioperative apalutamide plus ADT reduced the risk of metastasis or death by 20%. The next challenge is selecting who truly needs intensification. 🔗[doi.org/10.1038/s41391-026-0…] #ProstateCancer

RT @niklas_kluemper: 🧬 Great to see Jonathan @DrRosenbergMSK discussing NECTIN4 biomarkers and ADC sequencing in urothelial cancer at @Guar…

2) Tissue biomarkers refine disease biology but don't always select treatment. FGFR3 is an exception in mUC but also in earlier stages (where is ⬆️common). MoonRISe-1 takes this into NMIBC, delivering erdafitinib directly into the bladder to reduce systemic toxicity. @OncoAlert

3) Instead of looking at PD-L1, we could look at immune gene signatures. CD8 T cells are associated to response with ICI but not with BCG. Likely because different immunotherapies are likely to need different biomarkers How would that be translated into the vaccine trials?

An inspiring week at the GUARD International Symposium in Madrid and Prostate Cancer Lives Matter IV in Barcelona. Outstanding scientific discussions on prostate cancer and the great pleasure of reconnecting with friends and colleagues. Science and friendship at their best!